Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
API/Intermediate Imports from India Still Stalled, Traders’ Group Calls for Govt Schemes
API and intermediate imports from India are still stagnating due to logistics disruptions caused by the coronavirus pandemic, with a group of traders calling on the Indian and Japanese governments to set bilateral arrangements to facilitate trades. “If the impact…
To read the full story
Related Article
- Indian Export Restriction Lifted, but Japan Imports Still Stalled
April 10, 2020
- Big 3 Generic Maker Curbing Valsartan Shipments amid India Lockdown
April 6, 2020
- India Lockdown Derails Japan-Bound APIs, Intermediate Exports
March 30, 2020
- India’s API Export Curb Could Eventually Affect At Least 2 Firms, FPMAJ Finds
March 10, 2020
ORGANIZATION
- EFPIA Report Calls Japan a “Cautionary Tale” in 10-Country Biopharma Strategy Review
March 2, 2026
- Pharma Takes Harsh View of FY2026 Pricing Reform: Policy Group Survey
February 24, 2026
- JPMA to Push Govt to Scrap Market-Based Drug Price Revisions
February 20, 2026
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…